tiprankstipranks
Trending News
More News >
Addus Homecare (ADUS)
NASDAQ:ADUS

Addus Homecare (ADUS) AI Stock Analysis

Compare
334 Followers

Top Page

AD

Addus Homecare

(NASDAQ:ADUS)

Rating:77Outperform
Price Target:
$125.00
▲(10.36%Upside)
Addus HomeCare's strong financial performance and positive earnings call are the most significant factors contributing to the stock's score. While the technical analysis suggests stability, the valuation indicates moderate pricing. Challenges in staffing and Medicaid redetermination are noted risks, but the company's strategic growth and debt reduction efforts provide a positive outlook.
Positive Factors
Profitability
ADUS achieved a higher adjusted EBITDA than expected, indicating better profitability.
Revenue Growth
Hospice same-store revenues increased by 9.9% year-over-year, displaying strong growth in this segment.
Negative Factors
Medicaid Policy Changes
Investors are concerned about the GOP's plans to alter and cut Medicaid, which could adversely impact ADUS.
Trading Multiple
Lingering uncertainty around potential Medicaid policy changes has negatively impacted the company's trading multiple for the year to date.

Addus Homecare (ADUS) vs. SPDR S&P 500 ETF (SPY)

Addus Homecare Business Overview & Revenue Model

Company DescriptionAddus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.
How the Company Makes MoneyAddus HomeCare makes money primarily through reimbursed healthcare services, which are funded by a combination of government programs and private pay sources. Key revenue streams include personal care services, which involve non-medical assistance with activities such as bathing, dressing, and meal preparation. This segment is largely reimbursed through Medicaid and other similar state-managed programs. In addition, the company earns revenue from its home health services, offering skilled nursing and therapy services, which are reimbursed by Medicare, Medicaid, and private insurance. Hospice care, another significant revenue stream, provides end-of-life care and is reimbursed through Medicare, Medicaid, and private insurance as well. Addus HomeCare's earnings are influenced by its ability to maintain contracts with state and federal programs, manage regulatory compliance, and expand its service network through strategic acquisitions and partnerships.

Addus Homecare Earnings Call Summary

Earnings Call Date:May 05, 2025
(Q1-2025)
|
% Change Since: 8.53%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Positive
Addus HomeCare demonstrated substantial revenue and earnings growth with strong performance in the Personal Care and Hospice segments. Despite challenges in clinical hiring and the ongoing impact of Medicaid redetermination, the company has made significant strides in reducing debt and expanding operations through acquisitions.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
Total revenue for Q1 2025 was $337.7 million, a 20.3% increase compared to Q1 2024's $280.7 million.
Strong Earnings Growth
Adjusted earnings per share increased by 17.4%, from $1.21 in Q1 2024 to $1.42 in Q1 2025.
Personal Care Segment Success
The Personal Care segment achieved 7.4% same-store revenue growth and increased hiring success with 79 hires per day.
Hospice Segment Improvement
Hospice same-store revenue increased by 9.9% with a 4.6% rise in average daily census compared to Q1 2024.
Debt Reduction
Reduced bank debt by $20 million in Q1 2025, with an additional $20 million reduction early in Q2 2025, leaving a balance of $203 million.
Negative Updates
Challenging Clinical Hiring
Continued challenges in clinical hiring, particularly with geographic variability, although there have been improvements.
Medicaid Redetermination Impact
Ongoing impact from state-led Medicaid redetermination processes affecting admission volumes, particularly noted in Illinois.
Company Guidance
During Addus HomeCare's first quarter 2025 earnings call, the company reported total revenue of $337.7 million, marking a 20.3% increase compared to the same period in 2024. Adjusted earnings per share rose by 17.4% to $1.42, while adjusted EBITDA saw a 25.1% increase to $40.6 million. The company's Personal Care segment achieved a same-store revenue growth of 7.4%, with a 2% increase in same-store hours. The hospice segment experienced a 9.9% increase in same-store revenue, and the average daily census rose by 4.6% to 3,515. The home health division returned to positive growth with a 1.3% increase in same-store revenue. Addus reduced its bank debt by $20 million, leaving a balance of $203 million, and maintained a conservative net leverage position of under one time adjusted EBITDA. The company continues to benefit from funding received through the American Rescue Plan Act, utilizing $2.5 million in the first quarter, with $8.8 million remaining. Addus is also actively pursuing acquisition opportunities, with a focus on expanding its presence in Texas following the Gentiva personal care acquisition.

Addus Homecare Financial Statement Overview

Summary
Addus Homecare displays strong revenue growth and improving profit margins, with a solid cash flow generation capacity. However, a high debt-to-equity ratio and negative equity in 2024 present significant financial risks. Operational efficiency is commendable, but the balance sheet stability is a concern.
Income Statement
85
Very Positive
Addus Homecare demonstrated strong revenue growth, with a Revenue Growth Rate of 9.06% from 2023 to 2024. The Gross Profit Margin and Net Profit Margin have shown consistent improvement, reaching 32.48% and 6.37% in 2024, respectively. The EBIT Margin increased to 8.89%, indicating efficient cost management and operational profitability. These metrics reflect robust financial health and growth potential.
Balance Sheet
40
Negative
The company exhibits a high Debt-to-Equity Ratio due to negative equity in 2024, which is a concerning financial risk. The Return on Equity (ROE) is not meaningful due to negative equity. However, the company has managed its debt levels well historically, but the 2024 balance sheet indicates potential stability issues. The Equity Ratio fell to negative, highlighting significant financial leverage and risk.
Cash Flow
75
Positive
Addus Homecare shows a solid Free Cash Flow Growth Rate of 7.38% from 2023 to 2024, underscoring strong cash generation capabilities. The Operating Cash Flow to Net Income Ratio is robust, reflecting efficient cash operations. The Free Cash Flow to Net Income Ratio indicates that the company efficiently converts its earnings into cash. However, high investing outflows in 2024 could suggest aggressive growth strategies or capital expenditures.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.15B1.06B951.12M864.50M764.77M
Gross Profit
375.02M339.88M299.74M269.85M226.24M
EBIT
102.69M90.96M68.74M65.94M44.51M
EBITDA
120.61M106.56M83.14M80.70M57.18M
Net Income Common Stockholders
73.60M62.52M46.02M45.13M33.13M
Balance SheetCash, Cash Equivalents and Short-Term Investments
0.0064.79M79.96M168.90M145.08M
Total Assets
1.46B1.02B937.99M947.59M892.58M
Total Debt
273.13M175.18M178.05M253.77M230.39M
Net Debt
174.22M110.39M98.09M84.88M85.31M
Total Liabilities
442.14M317.73M304.45M373.24M373.91M
Stockholders Equity
970.49M706.69M633.54M574.34M518.68M
Cash FlowFree Cash Flow
110.38M102.79M96.81M34.84M102.58M
Operating Cash Flow
116.43M112.25M105.11M39.49M109.41M
Investing Cash Flow
-354.61M-119.24M-106.59M-42.02M-214.24M
Financing Cash Flow
272.30M-8.18M-87.45M26.34M138.19M

Addus Homecare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price113.27
Price Trends
50DMA
102.70
Positive
100DMA
108.69
Positive
200DMA
118.32
Negative
Market Momentum
MACD
2.91
Negative
RSI
61.74
Neutral
STOCH
78.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADUS, the sentiment is Positive. The current price of 113.27 is above the 20-day moving average (MA) of 109.84, above the 50-day MA of 102.70, and below the 200-day MA of 118.32, indicating a neutral trend. The MACD of 2.91 indicates Negative momentum. The RSI at 61.74 is Neutral, neither overbought nor oversold. The STOCH value of 78.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADUS.

Addus Homecare Risk Analysis

Addus Homecare disclosed 31 risk factors in its most recent earnings report. Addus Homecare reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Addus Homecare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$2.13B25.599.18%11.38%10.29%
NHNHC
76
Outperform
$1.62B15.1111.19%2.34%19.16%31.92%
76
Outperform
$1.25B33.935.00%54.81%-45.07%
71
Outperform
$3.08B34.647.85%5.34%
69
Neutral
$977.20M36.3511.28%30.04%43.47%
53
Neutral
$5.19B3.33-45.04%2.83%17.58%-0.66%
AGAGL
45
Neutral
$923.11M-42.95%19.18%-6.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ADUS
Addus Homecare
113.27
1.54
1.38%
AMED
Amedisys
93.61
-2.40
-2.50%
NHC
National Healthcare
103.96
1.00
0.97%
ASTH
Astrana Health
24.61
-15.45
-38.57%
PNTG
Pennant Group
27.86
4.57
19.62%
AGL
Agilon Health
2.35
-3.89
-62.34%

Addus Homecare Corporate Events

Business Operations and StrategyFinancial Disclosures
Addus HomeCare Reports Strong Q1 2025 Financial Results
Positive
May 5, 2025

On May 5, 2025, Addus HomeCare Corporation announced its financial results for the first quarter ended March 31, 2025, highlighting a 20.3% increase in net service revenues to $337.7 million and a 25.1% rise in adjusted EBITDA to $40.6 million. The company’s growth was driven by its personal care segment, which saw a 7.4% organic revenue increase, and the integration of Gentiva’s personal care operations. Addus also reported improvements in its hospice care segment and maintained a strong cash position, allowing for continued investment and potential acquisitions. The results reflect solid demand for home-based care services and strategic expansion efforts.

Executive/Board ChangesBusiness Operations and Strategy
Addus HomeCare Announces President’s Planned Retirement
Neutral
Mar 11, 2025

On March 10, 2025, Addus HomeCare announced the planned retirement of W. Bradley Bickham, its President and COO, effective March 10, 2026. His retirement is amicable, and he will remain in his role for another year to ensure a smooth leadership transition. Additionally, Addus extended CEO R. Dirk Allison’s employment agreement for three more years, emphasizing the company’s commitment to stable leadership as it continues its growth strategy. The company also granted restricted shares to executives, aligning with its compensation plans.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.